share_log

Exicure | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)

Exicure | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)

Exicure | SC 13D/A：超过5%持股股东披露文件(修正)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)
美股SEC公告 ·  08/05 18:27
Moomoo AI 已提取核心信息
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated July 31, 2024, indicates significant shareholding activities by CBI USA, Inc. and DGP Co., Ltd. CBI USA, Inc., a Delaware-based entity, reported beneficial ownership of 818,299 shares, representing 9.5% of Exicure's class of common stock. DGP Co., Ltd., based in the Republic of Korea, reported beneficial ownership of 3,060,000 shares, representing 35.4% of the class. The filing includes an amendment to the stock purchase agreement between DGP and OverdigmK, extending the closing date for the balance of the DGP Sale to September 30, 2024. Additionally, an assignment and waiver agreement was entered into, allowing for the termination or assignment of the DGP Sale Agreement to a third party at DGP's request. These documents were filed as part of Amendment No. 13 to the Schedule 13D, which amends and supplements the initial filing and subsequent amendments dating back to June 1, 2022.
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated July 31, 2024, indicates significant shareholding activities by CBI USA, Inc. and DGP Co., Ltd. CBI USA, Inc., a Delaware-based entity, reported beneficial ownership of 818,299 shares, representing 9.5% of Exicure's class of common stock. DGP Co., Ltd., based in the Republic of Korea, reported beneficial ownership of 3,060,000 shares, representing 35.4% of the class. The filing includes an amendment to the stock purchase agreement between DGP and OverdigmK, extending the closing date for the balance of the DGP Sale to September 30, 2024. Additionally, an assignment and waiver agreement was entered into, allowing for the termination or assignment of the DGP Sale Agreement to a third party at DGP's request. These documents were filed as part of Amendment No. 13 to the Schedule 13D, which amends and supplements the initial filing and subsequent amendments dating back to June 1, 2022.
生物技术公司Exicure, Inc. 在纳斯达克股票代码XCUR下交易，近期成为美国证券交易所(SEC) 13D/A日程表的内容。该文件的日期为2024年7月31日，显示了CBI USA, Inc. 和DGP Co., Ltd.的重大股权活动。总部位于特拉华州的实体CBI USA, Inc. 报告拥有818,299股，占Exicure普通股类别的9.5%的受益所有权。总部位于韩国的DGP Co., Ltd.报告拥有306万股，占该类别的35.4%。该文件包括了DGP与Overdigmk的股票购买协议的修正案，将DGP Sale的余额的截止日期延长至2024年9月30日。此外，还签署了一份让DGP请求终止或分配DGP Sale Agreement给第三方的让与和豁免协议。这些文件是作为Amendment No. 13附加修正和补充自2022年6月1日起的最初文件和后续修正文件而被提交的。
生物技术公司Exicure, Inc. 在纳斯达克股票代码XCUR下交易，近期成为美国证券交易所(SEC) 13D/A日程表的内容。该文件的日期为2024年7月31日，显示了CBI USA, Inc. 和DGP Co., Ltd.的重大股权活动。总部位于特拉华州的实体CBI USA, Inc. 报告拥有818,299股，占Exicure普通股类别的9.5%的受益所有权。总部位于韩国的DGP Co., Ltd.报告拥有306万股，占该类别的35.4%。该文件包括了DGP与Overdigmk的股票购买协议的修正案，将DGP Sale的余额的截止日期延长至2024年9月30日。此外，还签署了一份让DGP请求终止或分配DGP Sale Agreement给第三方的让与和豁免协议。这些文件是作为Amendment No. 13附加修正和补充自2022年6月1日起的最初文件和后续修正文件而被提交的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息